This content is from: Patents
Federal Circuit reverses Section 101 invalidation of life science patent
The Federal Circuit has ruled that the claims of a patent for liver cell treatment were not directed to a patent-ineligible concept, in a decision that provides guidance on how life science innovations can satisfy the Mayo test
Get Free Access to read more …
To read the full article, activate your free trial.
Get Free Access- Unlimited articles for one week
- No commitments; no payment details required
- Featuring IP strategy, copyright, patents, trademark and more!
Are you a Managing IP subscriber? Simply login here.